Loading
Life sciences · Journal article
The Indian Journal of Medical Research · September 29, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Background and objectives Doxorubicin is an effective chemotherapeutic agent, whose clinical use is limited by cumulative doxorubicin-induced cardiotoxicity. Early identification of myocardial injury is essential to prevent irreversible cardiac dysfunction. This study evaluated changes in cardiac function and circulating biomarkers associated with early doxorubicin-induced cardiotoxicity. Methods Left ventricular ejection fraction (LVEF) and global longitudinal strain (GLS) were assessed before and after chemotherapy. Circulating biomarkers, including high-sensitivity C-reactive protein (hs-CRP), high-sensitivity troponin I (hs-Troponin I), Interleukin-33 (IL-33), and miR126-3p, were analysed. Associations between biomarkers and echocardiographic indicators of subclinical cardiac dysfunction were evaluated. Results Significant reductions in LVEF (65.00±2.17% to 59.50±5.47%) and GLS (−19.04±1.87% to −15.37±1.79%), increased hs-CRP, and moderate elevations in IL-33 and significant reduction of miR126-3p were observed following doxorubicin therapy. There was a significant association between LVEF with hs-Troponin I ( P =0.03) and IL-33 ( P =0.04), whereas between GLS with hs-Troponin I ( P =0.04), IL-33 ( P =0.04), and miR126-3p ( P= 0.006). Among biomarker inter-association, hs-Troponin I was highly significantly associated with IL-33 ( P <0.01), whereas no significant associations were observed between hs-CRP and other biomarkers. Interpretation and conclusions Early alterations in left ventricular function and circulating biomarkers were associated with doxorubicin chemotherapy; GLS and hs-Troponin I were associated with myocardial dysfunction, while IL-33 and miR126-3p showed additional associations with strain parameters.